Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) As of 07/11/2025 10:55 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock STAB vs. NAVB, SCPS, VAXX, EVLO, CMRA, GNCAQ, GNCA, ARDS, EFTR, and HSTOShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), eFFECTOR Therapeutics (EFTR), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Its Competitors Navidea Biopharmaceuticals Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals eFFECTOR Therapeutics Histogen Navidea Biopharmaceuticals (NYSE:NAVB) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation. Do institutionals and insiders hold more shares of NAVB or STAB? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Statera Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor NAVB or STAB? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Statera Biopharma Neutral Is NAVB or STAB more profitable? Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Statera Biopharma N/A N/A N/A Which has more risk & volatility, NAVB or STAB? Navidea Biopharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Which has higher valuation & earnings, NAVB or STAB? Statera Biopharma has lower revenue, but higher earnings than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K2.46-$15.18MN/AN/AStatera BiopharmaN/AN/AN/AN/AN/A SummaryNavidea Biopharmaceuticals beats Statera Biopharma on 4 of the 4 factors compared between the two stocks. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5K$879.82M$5.62B$9.10BDividend YieldN/A4.84%5.24%4.00%P/E RatioN/A1.3828.1320.27Price / SalesN/A239.36428.6398.72Price / CashN/A17.6937.4658.16Price / BookN/A6.588.045.49Net IncomeN/A-$23.83M$3.18B$250.45M7 Day PerformanceN/A1.59%3.62%4.78%1 Month PerformanceN/A12.08%4.05%7.67%1 Year PerformanceN/A4.39%30.00%16.43% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020NAVBNavidea BiopharmaceuticalsN/A$0.00-80.0%N/A-80.0%$20K$8.13K0.0010Gap DownHigh Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00flatN/A-100.0%$13KN/A0.0090Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions VolumeCMRAComera Life SciencesN/A$0.00flatN/A-99.3%$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5K$3.09M0.0030News CoverageEFTReFFECTOR Therapeutics0.0815 of 5 stars$0.00flatN/A-99.4%$1K$3.55M0.0010Gap DownHSTOHistogenN/A$0.00-98.0%N/AN/A$1K$19K0.0020Gap Down Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Scopus BioPharma Competitors Vaxxinity Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors eFFECTOR Therapeutics Competitors Histogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STAB Stock Alerts